Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 2, 2000, Pages 171-179

  Vermes, A ^a   Guchelaar, H J ^a   Dankert, J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DRUG METABOLITE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; FUNGAL DNA; FUNGAL RNA; ITRACONAZOLE; KETOCONAZOLE; MAGNESIUM HYDROXIDE; PYRROLE DERIVATIVE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANDIDIASIS; CHROMOMYCOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DIARRHEA; DNA SYNTHESIS; DRUG ACTIVITY; DRUG CONCENTRATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; GLOMERULUS FILTRATION; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MONOTHERAPY; MOUSE; NAUSEA; NONHUMAN; RNA SYNTHESIS; SYSTEMIC MYCOSIS; VOMITING;

EID: 0033869563     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.2.171     Document Type: Article

References (73)

1. Effective systemic antifungal agents
2. The synthesis of 5-fluoropyrimidines
3. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors
4. Chemotherapeutic activity of 5-fluorocytosine
5. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent
6. Clinical use of systemic antifungal agents
7. Flucytosine
8. Mode of action of 5-fluorocytosine
9. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans
10. Anti-Candida drugs-the biochemical basis for their activity
11. Mode of action of 5-fluorocytosine and mechanisms of resistance
12. 5-Fluorocytosine-current status with special references to mode of action and drug resistance
13. Antifungal agents
14. Flucytosine
15. Mechanisms of action of 5-fluorocytosine
16. Mode of action of 5-fluorocytosine
17. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata
18. Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species
19. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
20. Strategies in the treatment of systemic fungal infections
21. Older drugs
22. Clinical pharmacokinetics of systemic antifungal drugs
23. Flucytosine kinetics in subjects with normal and impaired renal function
24. Flucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance. Studies in man
25. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function
26. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection
27. Peritoneal clearance of amphotericin B and 5-fluorocytosine
28. Flucytosine: Correlation between toxicity and pharmacokinetic parameters
29. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
30. Treatment of fungal infections with flucytosine
31. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
32. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
33. Treatment of cryptococcal meningitis with high dose, long-term combination amphotericin B and flucytosine
34. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B
35. Cryptoccocal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment
36. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
37. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial
38. Cryptococcal disease: Implications of recent clinical trials on treatment and management
39. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole
40. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis
41. Treatment of experimental cryptococcal meningitis with fluconazole: Impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome
42. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS
43. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
44. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
45. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications
46. Synergistic action of amphotericin B and 5-fluocytosine against yeast-like organisms
47. Synergism of amphotericin B and 5-fluorocytosine for Candida species
48. Candida endophthalmitis: Clinical presentation, treatment and outcome in 23 patients
49. Candida endocarditis treated with 5-fluorocytosine
50. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome
51. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis
52. Antifungal treatment of Candida peritonitis in continous ambulatory peritoneal dialysis patients
53. Antifungal agents. Part I. Amphotericin B preparations and flucytosine
54. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: A double-blind, placebo-controlled study
55. Fluconazole vs. itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study
56. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice
57. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses
58. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
59. Successful treatment of chromoblastomycosis with 5-fluorocytosine
60. Treatment of chromomycosis with ketoconazole and 5-fluorocytosine
61. Genetic delivery of enzymes for cancer therapy
62. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
63. Bone marrow toxicity associated with 5-fluorocytosine therapy
64. Severe candidiasis associated with thymic dysplasia, IgA deficiency, and plasma antilymphocyte effects
65. Fatal aplastic anemia resulting from flucytosine
66. Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry
67. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: Possible factor in 5-fluorocytosine clinical toxicity
68. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients
69. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
70. Flucytosine conversion to fluorouracil in humans: Does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy
71. An accelerated stability study of 5-flucytosine in intravenous solution
72. Clinical problems with 5-fluorocytosine
73. Systemic antifungal agents. Drug interactions of clinical significance